When statistics don’t appear to synchronize with consumer experience, it may be time to look more closely at direct influences behind medicine expenses, a Pharmaceutical Research and Manufacturers of America (PhRMA) expert suggested recently.
New research from Boston Healthcare Associates on biologic therapies for rheumatoid arthritis (RA) suggests that those therapies have benefits for patients who exceed their value as understood when they were initially approved.
Real Endpoints recently conducted research that found significant variability in treatment preferences among multiple sclerosis patients, as well as a difference in how patients define value in MS therapies compared to payers and physicians.
The Pharmaceutical Research and Manufacturers of American recently hosted the “Through the Microscope: Examining Modern Medicine” national health care discussion series sponsored as part of the new GOBOLDLY campaign.
Medicare Part D has helped seniors and people living with disabilities receive their prescriptions for a decade with 90 percent or more of beneficiaries reporting satisfaction with this part of their Medicare coverage.